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In this issue of Neuron, Richardson-Jones et al. report on a novel genetic approach to conditionally and
specifically dampen the function of the 5-HT1A autoreceptor in mice to study its role on the 5-HT system
and on the antidepressant-like effect of the selective serotonin reuptake inhibitor (SSRI) fluoxetine.Major depressive disorder (MDD) carries
the largest burden of all diseases inmiddle
and high income countries, as determined
by the World Health Organization (2008).
SSRIs are generally usedas first-line treat-
ment in the treatment of MDD. It is there-
fore imperative to understand their mech-
anism of action in order to improve the
effectiveness of the treatment of MDD.
Indeed, only about a third of patients
withMDDwill remit in a first trial with these
agents (Trivedi et al., 2006).
It is well known that SSRIs rapidly
inhibit the serotonin (5-hydroxytryptamine
[5-HT]) transporters, within hours, and yet
begin to exert an antidepressant response
well after they achieve a steady-state level
in the human brain. The increase in 5-HT
transmission in forebrain areas, which
should result frompreventing the reuptake
of 5-HT in presynaptic terminals, is likely
dampened by a decrease in firing of
5-HT neurons because 5-HT reuptake is
also inhibited at their cell body level. This
was first documented in 1983 upon exam-
ining the effects of an SSRI in the rat
brain (Blier and de Montigny, 1983). The
receptor mediating this initial decrease of
the firing of 5-HT neurons was subse-
quently identified as a 5-HT1A receptor
and identified on the 5-HT neurons them-
selves (Verge´ et al., 1985). This autorecep-
tor desensitizes over the course of 2–3
weeks of SSRI administration, thus allow-
ing a recovery to normal of the firing of
5-HT neurons in the presence of reuptake
inhibition. This results in a marked
increase in 5-HT transmission in projec-
ting areas because 5-HT release is highly
dependent on firing. The desensitization
of the 5-HT1A autoreceptor thus corre-
sponds in time with the onset of action of
SSRIs in MDD.Dr Rene´ Hen’s group reports herein
extensive experiments to advance our
knowledge on the role of this 5-HT1A
autoreceptor in the antidepressant-like
response in mice (Richardson-Jones
et al., 2010). Their contribution represents
a landmark in this field for several reasons,
emphasized in this Preview. First, they
generated mice with a conditional sup-
pression of the expression of 5-HT1A
autoreceptors in the raphe nuclei, without
affecting the postsynaptic 5-HT1A recep-
tors in projecting areas of the 5-HT
neurons. The engineering of these mice
represents a major advancement above
the production of constitutional null
mutantmice for the5-HT1A receptor (Ram-
boz et al., 1998), since knockout mice do
not allow for deciphering the role of this
receptor in adulthood from that of changes
that may have occurred during develop-
ment in the absence of the receptor.
Furthermore, the 5-HT1A receptors are
located both pre- and postsynaptically,
where they exert opposite functions on
overall 5-HT1A transmission. Therefore, in
constitutional 5-HT1A knockout mice,
postsynaptic 5-HT1A transmission is abol-
ishedwhereas that atother5-HTreceptors
may be enhanced due to increased 5-HT
neuron function.
Although the density of 5-HT1A autore-
ceptors in the raphe was decreased only
by about 30% in their mice, the physiolog-
ical impact was major. Overall, the aver-
age firing rate of 5-HT neurons in the
dorsal raphe of these 1A-Low mice was
double that of 1A-High mice. There was
still an overlap in the firing rates of neurons
in the two groups, likely resulting from
about half the 5-HT neurons having lost
their responsiveness to a 5-HT auto-
receptor agonist in the 1A-Low miceNeuronand half retaining normal sensitivity.
Behaviorally, the 1A-Low and 1A-High
mice did not exhibit differential baseline
anxiety in two conflict-based models. In
contrast, after a few weeks of repeated
stress, the 1A-Low mice displayed less
behavioral despair in depression-related
stress paradigms.
It is interesting to note that, although
the significant differences between the
groups ofmice in these behavioral models
were not large, they were of the same
magnitude as the decreased expression
of the 5-HT1A autoreceptor. These 1A-
High and 1A-Low mice may thus have
clinical relevance for understanding the
effects of the human polymorphism
C(1019)G for the 5-HT1A receptor (Lem-
onde et al., 2003), where C carriers tenta-
tively express lower 5-HT1A autoreceptor
levels than the G carriers.
In order to address whether the antide-
pressant-like response to an SSRI could
differ in mice with a differential expression
of the 5-HT1A autoreceptors, Hen’s group
used the novelty suppression feeding test,
which is sensitive to acute benzodiaze-
pine administration, but only to prolonged
use of antidepressant drugs (Merali et al.,
2003). In this paradigm, the 1A-High
mice did not respond to prolonged SSRI
administration, but the 1A-Low presented
an antidepressant-like response to the
SSRI, after both an 8 day and a 26 day
regimen. These results first suggest that
this specific paradigm in this particular
strain of mice may be conceived as
a human equivalent to SSRI response
(1A-Low) and resistance (1A-High). Sec-
ond, they imply that the more rapid onset
of behavioral action presumably resulted
from the already dampened sensitivity
of 5-HT1A autoreceptors, not requiring65, January 14, 2010 ª2010 Elsevier Inc. 1
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Previewsprior desensitization before obtaining
enhanced 5-HT transmission by the
SSRI. This interpretation was supported
by the greater enhancement of extrasy-
naptic 5-HT levels, measured using mi-
crodialysis in two depression-related
brain structures, with an acute SSRI
challenge in drug-naive 1A-Low mice
when compared to 1A-High mice. The
baseline levels of 5-HT were, however,
identical at baseline. Furthermore, the
levels of 5-HT were enhanced after
only 8 days of SSRI administration in
the 1A-Low mice, but not in the in the
1A-High mice. Nevertheless, 5-HT
levels were similar after long-term
SSRI administration in both groups of
mice. This was consistent with the
demonstrated capacity of the 5-HT1A
autoreceptors to desensitize in the
1A-High mice.
In summary, this work by Hen’s group
has permitted the examination of the
5-HT system by partially turning off the
5-HT1A autoreceptor at a specific point
in time, allowing correlations to be made
between alterations of 5-HT transmission
and some antidepressant-like responses.
While the study provides important new
insights, there are also some caveats
that should be considered more generally
when using animal paradigms to mimic
MDD in laboratory animals. Since many
symptoms of MDD are subjective in
nature and not always directly observable
in patients, we can never be sure that the
depressive syndrome is faithfully repro-
duced. An additional issue when using
these models is which mouse strain
would best represent the patient profile,
since MDD is a heterogeneous condition
in terms of symptoms presentation. For
instance, the wild-type mice used in a
prior Science paper from this group re-
sponded to prolonged administration of
a SSRI (Santarelli et al., 2003), in contrast
to a lack of response in the unaltered
1A-High mice strain. Nevertheless, the
models used in this paper had sufficient
face validity to test their hypothesis.
Finally, one has to additionally consider
that there is likely a variety of altered
neuronal elements that could contribute
to the pathogenesis and/or the treatment
response in MDD, even within the 5-HT
system. For instance, beyond the 5-HT1A
polymorphism, there is as well the poly-
morphismfor the5-HT transporter (Murphy2 Neuron 65, January 14, 2010 ª2010 Elsevieet al., 2008). Theremay evenbesynergistic
action between such neuronal elements in
explaining SSRI response, or lack of, in
depressed patients (Arias et al., 2005).
For the Future
The present paper leaves us with some
open questions for future consideration.
For instance, one would have expected
a behavioral response after the long-term
SSRI administration in the 1A-High mice
given that 5-HT levels were enhanced to
the same extent in the hippocampus and
frontal cortex as in 1A-Low mice. While
the authors initially postulated ‘‘that
5-HT1A-mediated serotonergic tone prior
to treatment is critical for establishing
treatment response,’’ their later proposal
of ‘‘subtler differences in serotonergic
tone’’ is possibly amore likely explanation.
Microdialysis assesses the extracellular
levels of neurotransmitters which may not
always reflect their synaptic concentra-
tions. The synaptic release of 5-HT per
electrical impulse is more under the
control of the terminal 5-HT1B autorecep-
tor than that of the 5-HT transporter (Cha-
put et al., 1986). The 5-HT1B autoreceptor,
which also desensitizes after prolonged
SSRI administration (Pin˜eyro and Blier,
1999), may have downregulated its func-
tion to a greater extent in the 1-Low than
in the 1-High mice.
Related to methodological issues is the
assessment of the degree of desensitiza-
tion of the 5-HT1A autoreceptor. Using
the hypothermia response in mice, it
appears that the desensitization was of
the all or none fashion following SSRI
administration. Using electrophysiological
approaches, prolonged SSRI administra-
tion generally produces a 2- to 3-fold shift
to the right of the dose-response curve to
a cell body 5-HT autoreceptor agonist
(Pin˜eyro and Blier, 1999). As mentioned
by the authors, a different degree of
5-HT1A autoreceptor desensitization may
well be present in SSRI-treated 1A-High
and 1A-Low mice. The spontaneous
firing rate of 5-HT neurons may thus be
differentially affected by the long-term
SSRI regimen in 1A-Low and 1A-High
mice. The latter two parameters could be
investigated using electrophysiological
techniques.
In closing, the paper by Richard-Jones
et al. has provided evidence for alterations
in the function of 5-HT neurons in ther Inc.presence of altered 5-HT1A autoreceptor
expression. These findings may help us
understand why G carriers of the 1029
5-HT1A polymorphism may not respond
as well to serotonergic drugs (Lemonde
et al., 2004). Such research endeavors
are also useful for better understanding
the poor remission rates obtained with
a first antidepressant medication and for
providing support for optimizing thera-
peutic interventions on the basis of the
heterogeneity of patients with regard to
the function of their 5-HT and, eventually,
other neurotransmitter systems.
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